Genfit stock rallies 20% after hours on data for liver disease drug

Anatomy of human body with liver. 3d illustration

Mohammed Haneefa Nizamudeen

Shares of Genfit (NASDAQ:GNFT) shot up 20% in after-hours trading Monday after the biotech company and partner Ipsen (OTCPK:IPSEY) announced the presentation of positive results from a Phase 3 study of their drug elafibranor in the treatment


This website uses cookies. By continuing to use this site, you accept our use of cookies.